Navigation Links
EUPROBIO 2008 Presentation to Highlight Latest Immune Research

Presentation to focus on a new dietary supplement resulting from years of study by leading research scientists in Russia, Ukraine and Bulgaria,

Del-Immune V

BOULDER, Colo., Oct. 6 /PRNewswire/ -- On Thursday, October 16, 2008 at the EUPROBIO 2008 Conference, an abstract entitled "Immune regulatory cytokines Del-Immune V(R) induction and its impact on cytotoxicity of natural killer cells" will be presented to physicians, researchers and educators. Attendees to the presentation will learn about the latest advancements in this field of research. After seeing the study abstract, conference organizers made last-minute changes to the conference schedule to include a presentation of this groundbreaking research.

The abstract is based on a recent study focusing on Del-Immune V(R), a new immunomodulator containing DNA and peptoglycan fragments of lactobacillus rhamnosus V. The study, which confirms that this formulation enhances immune function, was conducted in the Ukraine by several of Europe's foremost research scientists.

Among other findings, the study demonstrated that daily administration of Del-Immune V(R) within 5 days raised a level of circulating interferon up to 4.2+/-0.5 log2 u/ml (P <0.05) against 2.0+/-0.3 log2 u/ml of the controls. Interferons are the switches that help cells resist viral infection and provide the initial, crucial immune response to immune challenges. The results of this latest research demonstrate the immune modulator activity of Del-Immune V(R) and the potential value the dietary supplement may have in clinical situations.

Del-Immune V(R) is a dietary supplement containing a natural culture that starts with healthy bacteria originally found in unpasteurized milk. Unique technological processing of the Del-Immune V(R) formulation creates a natural immunostimulant. The study described above and other research indicates that Del-Immune V(R) could be beneficial in assisting the body in its natural role of protecting the body from germs, viruses and other bodily invaders.

Del-Immune V(R) dietary supplements are produced in the United States. Thousands of people take Del-Immune V(R) on a regular basis and doctors have reported positive results, including an enhanced resistance to cold and flu and a restorative effect on the immune system.

The EUPROBIO 2008 Conference will be held October 15-18, 2008 in Cracow, Poland at Auditorium Maximum.


Pamela Sichel

Pure Research Products, LLC


This release was issued through eReleases(TM). For more information, visit

SOURCE Pure Research Products, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Strategic Diagnostics Updates Roth Conference Presentation Time
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
11. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
Post Your Comments:
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: ) The ... enhanced security to access and transact across channels. ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):